ReviewWorld journal of transplantation2020
Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches.
Review in World journal of transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation: a case report, meta-analysis, and systematic review.Diagnostic pathology · 2024Pooled it
- Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies.Molecular therapy. Oncology · 2026Article
- Path beyond the blind end-unravel the imaging spectrum of appendiceal pathologies.Abdominal radiology (New York) · 2026Review
- Immunomodulatory Strategies for Managing Viral Infections in Solid Organ Transplantation: Progress and Challenges.Current microbiology · 2026Review
- Ocular complications after liver transplantation: A comprehensive review of infectious and non-infectious etiologies.World journal of transplantation · 2026Review
- Allograft-localized post-transplant lymphoproliferative disorder in a pediatric kidney transplant recipient: a case report and focused review.BMC pediatrics · 2026Review
- A Rare Finding at the Hepaticojejunostomy in a Postliver Transplant Patient.ACG case reports journal · 2026Article
- A Case of Post-Transplantation Lymphoproliferative Disorder Following Kidney Transplantation.Case reports in nephrology · 2026Article
- Early Posttransplant Lymphoproliferative Disorder and Cryptosporidiosis After Liver Transplantation.Case reports in medicine · 2026Article
- Post-transplant lymphoproliferative disorder after solid organ transplantation: a comprehensive review.Frontiers in transplantation · 2026Review
- Refractory Epstein-Barr Virus-Negative Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder in a Renal Transplant Patient Treated With Bispecific Antibody Therapy.Journal of medical cases · 2026Article
- Lipid-based Nanoparticles as Drug Delivery System for Modern Therapeutics.Pharmaceutical nanotechnology · 2026Review
- A Case of Epstein-Barr Virus-Associated Transplanted Kidney Post-Transplant Lymphoproliferative Disorder Complicated by Hemophagocytic Lymphohistiocytosis, Six Years after Transplantation.Surgical case reports · 2026Article
- Optimizing patient outcomes in interstitial lung disease through pre- and post-transplant management strategies.World journal of transplantation · 2025Review
- Synthesis and Antiviral Evaluation of Unexplored Dioxolane-Derived 7‑Deazapurine Nucleoside Analogues against Epstein-Barr Virus (EBV).ACS medicinal chemistry letters · 2025Article
- Autopsy Case of Epstein-Barr Virus-associated T-cell Post-transplant Lymphoproliferative Disorder with Mono- and Polymorphic Lesions: Possibility of 'Polymorphic T-cell Post-transplant Lymphoproliferative Disorder'.Internal medicine (Tokyo, Japan) · 2025Article
- Review
- Epstein-Barr Virus-Negative Plasmablastic Lymphoma Post-liver Transplantation.ACG case reports journal · 2024Article
- Posttransplant Lymphoproliferative Disorder in a Patient With Alpha-1 Antitrypsin Deficiency: A Case Report.Cureus · 2024Article
- Long-term Safety in Epstein-Barr Virus-Seropositive Kidney-only Transplant Recipients Treated With Belatacept in Clinical Practice: Final Study Results From the ENLiST Registry.Transplantation direct · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transplant recipients are vulnerable to a higher risk of malignancy after solid organ transplantation and allogeneic hematopoietic stem-cell transplant. Post-transplant lymphoproliferative disorders (PTLD) include a wide spectrum of diseases ranging from benign proliferation of lymphoid tissues to frank malignancy with aggressive behavior. Two main risk factors of PTLD are: Firstly, the cumulative immunosuppressive burden, and secondly, the oncogenic impact of the Epstein-Barr virus. The latter is a key pathognomonic driver of PTLD evolution. Over the last two decades, a considerable progress has been made in diagnosis and therapy of PTLD. The treatment of PTLD includes reduction of immunosuppression, rituximab therapy, either isolated or in combination with other chemotherapeutic agents, adoptive therapy, surgical intervention, antiviral therapy and radiotherapy. In this review we shall discuss the prevalence, clinical clues, prophylactic measures as well as the current and future therapeutic strategies of this devastating disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.